A series of basic carboxamides of actagardine ( 1) , a lantibiotic possessing good antistreptococcal activity, were synthetized. Some physico-chemical characteristics, in particular charge and lipophilicity, that influence water solubility were determined. The in vitro and in vivo activity was evaluated. The monocarboxamides were generally more active than actagardine against selected Gram-positive bacteria. The 3,3-dimethylamino-l-propylamide hydrochloride (4) showed good water solubility, bactericidal action and favourable antibacterial activity and it appears to be a suitable drug for further investigation.
A series of basic carboxamides of actagardine ( 1) , a lantibiotic possessing good antistreptococcal activity, were synthetized. Some physico-chemical characteristics, in particular charge and lipophilicity, that influence water solubility were determined. The in vitro and in vivo activity was evaluated. The monocarboxamides were generally more active than actagardine against selected Gram-positive bacteria. The 3, hydrochloride (4) showed good water solubility, bactericidal action and favourable antibacterial activity and it appears to be a suitable drug for further investigation.
Actagardine (iy~3) is a lanthionine-containing polypeptide antibiotic, belonging to the family of lantibiotics,4) whose structure was recently elucidated.5) It consists of 14 aliphatic amino acids (including one lanthionine and three £-methyllanthionines) and one aromatic (tryptophan) amino acid which generate a polypeptide chain where thioether bridges form four rings. It possesses one acidic function belonging to the glutamic acid side chain (7-COOH). The terminal amino and carboxyl groups belong to the alanine moieties of two £-methyllanthionines. The sequence is shown in Fig. 1 . FAB-MSmeasurements5* account for one more oxygen, whoseposition has not yet been established. Actagardine, as well as its related compounddesignated as metabolite D,3) possesses good in vitro activity against Gram-positive bacteria, particularly Streptococci, and obligate anaerobes.3>6) It shows a good in vivo efficacy in experimental Streptococcus pyogenes septicemia in the mouseupon subcutaneous administration and low toxicity (mice, ip). Its mechanismof action consists in the specific inhibition of peptidoglycan biosynthesis in the bacterial cell wall.7) The need to improve the biological properties of actagardine prompted us to prepare some chemical derivatives. As a preliminary approach a series of basic monocarboxamides (2~10) was synthesized. Two diamides (ll and 12) and one iV-acyl derivative (13) were also prepared. (1). SEPT. 1990 e Actagardine (acid form) is insoluble in water. The value given is logP between w-octanol and 0.1 Mphosphate nd: Not determined.
Chemistry
Compounds 2-10 (Table 1) were obtained by reaction of actagardine (1) with the selected amines in iVyV-dimethylformamide (DMF) in the presence of diphenylphosphorylazide (DPPA) at 0-5°C. An excess of the reactant was used to minimize side reactions involving either the free amino function of actagardine or the unprotected primary or secondary aminogroups of the reactant itself. A sufficientamount of triethylamine (TEA) was added to catalyze the reaction and to free the base when the hydrochloride of the reactant was used.
For the synthesis of the iV-di(2-aminoethyl) monocarboxamide (5) protection of the primary amino groups of diethylenetriamine by way of the benzylidene group was necessary. The protecting functions of the dibenzylidene intermediate, which was not isolated, were then removed with diluted HC1at room temperature.
Whenthe amidating agent was ethylamine or glycine ethyl ester diamides ll and 12 were obtained. This is somewhat surprising and difficult to be interpreted considering that the same 1 :4 molar ratio of actagardine to the amine was used. The only difference is the structure of the reacting amines and the isoelectric point of the final amides. In fact, basic monocarboxamides were obtained with amines carrying additional amino groups, while only dicarboxamides were obtained when a monoalkylamine or an amino (R, R' and R" see Fig. l acid ester wasused. Finally, the treatment of actagardine with an activated alkyl ester led to the acylation of the terminal amino group (compound 13). The structure of the 3,3-dimethylamino-l-propylamide hydrochloride (4) was confirmed by lH NMRstudies5). All the signals of the core peptide were present. In particular, a strong NOEeffect between the amide proton of the propylamino side chain and the CHaresonance of the terminal alanine demonstrated that the amide formation occurs at the Ala-19 residue. The structures of the other amide derivatives were established by analogy of their lH NMR spectra with that of compound 4.
The IR spectra of these compoundswere substantially unmodified with respect to that of actagardine. They were in accordance with the polypeptide structures but were not diagnostic enough for the formation of new amide bonds because of the presence of the initial strong peptide bands (1660, 1525 and 1235 cm1). Only for compound 12 a band at 1740cm1 (vc=o ester) confirmed the presence of the ethylglycine moiety. The UVspectra showed the same absorption pattern as in actagardine3) indicating that the tryptophan unit was unaffected.
Acid-base titrations in methylcellosolve (MCS) -H2O (4 : 1) showed that additional basic functions were present in compounds2^10, but were absent in compounds11~~13. The equivalent weights (EWs), determined in non-aqueous solvents for each compound by titration with hydroxytetrabutylamine (HTBA) in pyridine and/or perchloric acid in acetic acid, were in accordance with the structures assigned. Preliminary data of the water solubility at neutral and slightly acidic pH indicated that a certain degree of correlation exists between solubility and basicity of these derivatives, the most basic compounds 2~6 being the most soluble. In particular, the amide 4 was about 60 times more soluble than actagardine at pH 4 and about 4 times at the physiological pH.
Biological Activity All the compoundsshowedan antibacterial activity similar to that of actagardine (1) . With the exception of compound13, the carboxamides were generally more active than actagardine with MICs2 to 8 times lower than those of the parent compound ( Table 2 ). The inoculum size did not influence the in vitro activity nor did the presence of serum. The compounds showed a high activity against & pyogenes, Streptococcus salivarius, and Streptococcus mitis: cdmpounds 8 and 10 were the most active in particular on S. salivarius (MIC: 0.05 fig/ml) and S. mitis (MIC: 0.8 //g/ml), while against S. pyogenes compounds 2 and 3 showed the highest activity (MIC: 0.2 #g/ml). The compoundswere less active against the other Streptococci tested.
All monocarboxamides (2-10) had excellent efficacy in the murine model of S. pyogenes septicemia upon sc administration (Table 3) being 2-4 times more effective than actagardine. In contrast, diamides ll and 12 were less active in vivo than the unmodified antibiotic, likely due to their low hydrosolubility at the physiological pH. None of these amides was effective orally up to 300mg/kg, as was the parent compound.
Amongthe monocarboxamides the 3,3-dimethyl-l-propylamide hydrochloride (4) was selected for further evaluation. Its bactericidal activity was determined in comparison with actagardine (Fig. 2) . Against growing cells of S. pyogenes compound4 showed a bactericidal activity comparable to that of actagardine, but at lower concentrations. For both antibiotics 99%and >99.9% of cells were killed within 5 and 24 hours of incubation with concentrations 10 times the MIC; for the amide 4 at least 99.9% killing was obtained after 24 hours of exposure to a con- O Control, å¡ actagardine (1.6/zg/ml), V actagardine (16/zg/ml), å² compound 4 (0.4#g/ml), à" compound 4 (4 //g/ml). The pharmacokinetic of compound4 in the mouse serum was studied at a dose of 20mg/kg sc (Fig. 3) . Peak level was attained by the first time point (10 minutes), then levels declined with an apparent terminal t1/2 of.3 hours; the area under the curve was 27.4#g-hour/ml. The very high concentrations found in the urine (about 1,000//g/ml at 1 hour and 500//g/ml at 4 hours) indicated that the compound is excreted through the kidney. The LD50 in mice was 1,225 mg/kg, ip and 700mg/kg, iv. Though limited to one compound, the negligible antibacterial activity ofJV-acyl derivative (13) (Table 2) indicated that this type of modification is very likely to be detrimental to the antimicrobial properties of actagardine.
Experimental
Evaporation of solvents was carried out with a rotary evaporator at 40°C under reduced pressure. The reactions were monitored by TLC on Silica gel plates (F254, Merck) developed with a CH3CN-0. 1 Mphosphate buffer pH 7.0 mixture (75 : 25, for the piperazinyl derivatives; 60 : 40, for the other compounds). The spots were detected by both UVlight at 254nmand charring with H2SO4at 120°C. The homogenicity of final products was checked by HPLCanalyses which were performed on a column Hibar (250x 4mm; Merck) prepacked with LiChrosorb RP-8 (10//m), using a Waters chromatograph equipped with a pump Mod. M45, a UVdetector Mod. 440 at 254nmand connected to a data system SP 4000 (Spectra Physics), and a 20-/d loop injector Rheodyne Mod. 7125. Mobile phase: CH3CN-0.1 m phosphate buffer pH 7.5 (40 : 60). Flow rate: 1 ml/minute. IR spectra (Nujol) were recorded with a Perkin-Elmer Mod. 580 spectrometer. UVspectra were recorded with a Perkin-Elmer Mod. 320 UV-VISspectrophotometer in MeOH solution.
Acid-base titrations were carried out in both aqueous MCS-H2O(4 : 1) and non-aqueous (pyridine or AcOH)solvents. The PKMCSvalues of the additional basic functions were determined in MCS-H2O(4 : 1) solution by titration of the compounds with 0.01 N NaOH.The presence of the free amino group of actagardine (pATMcs6.3) in the derivatives was confirmed by titration with 0.01 N HC1. The EWswere obtained by titration with either HTBAin pyridine or HC1O4in AcOH.
Partition coefficients (log P) were determined between «~octanol and H2Oin distilled water (pH 7) and in 0.1m acetate buffer (pH 3.0). The concentration of the products in each phase was determined spectrophotometrically (UV).
Basic Monocarboxamides (Compounds 2^10) General Procedure: To a stirred solution of 1 mmolof actagardine (1) and 4mmolof the appropriate diamine in 100ml of DMF,a solution of 2.5 mmol of DPPAin 20ml of DMFwas added dropwise over 30 minutes while cooling at 0^5°C. The reaction mixture was kept at 5°C for 6 hours and at room temperature overnight. On adding 500 ml of Et2O a solid separated which was collected, washed with 100 ml of Et2O, and redissolved in 500ml of a BuOH-H2O-MeOH (45 :45 : 10) mixture. The organic layer was separated, washed with 100ml of H2O, and then concentrated to a small volume. On adding Et2O, a solid separated which was collected and washed with Et2O. The crude material so obtained showed at least four spots by TLC. It ( ; 50-ml fractions were collected which were checked by TLC. Those containing the desired pure product were pooled, one volume of BuOHwas added to prevent foaming, and then most of the CH3CN was evaporated. The remaining solution was extracted with H2O;afterward the organic phase was concentrated to a small volume. Onstanding at room temperature overnight (in some cases cooling was necessary) a solid separated which was collected, washed with Et2O, and then dried under vacuum at 50°C overnight. The title compoundswere so obtained as the free bases.
Compound 4
To a stirred solution of 1 mmolof actagardine 3,3-dimethylamino-l-propylamide, prepared as described above, in 200ml of H2O, 10ml of0. 1 N HC1 was added dropwise while cooling at 5°C. The resulting solution (pH 4.95) was extracted with BuOH, and then the organic layer was separated and concentrated to a small volume. Onaddition of Et2O, a solid separated which was collected, washed with Et2O, and then dried under vacuum at 50°C overnight, yielding the title compound, as the hydrochloride.
Compound 5 By treatment of actagardine with dibenzylidenediethylenetriamines as described in the above general procedure, the diprotected amide was obtained, which was dissolved (1 g) in 200ml of a 0.1 N HC1-DMF (9 : 1) mixture at room temperature with stirring. After standing overnight, 250ml of BuOHwas added. The aqueous layer was adjusted at 7.0 with a 3%(w/v) aqueous NaHCO3and the organic layer was separated; afterward it was concentrated to a small volume. On adding Et2O, a solid separated which was collected, washed with Et2O, and then it was purified on a silica gel column as previously described.
Compound 9
To a stirred solution of 1 mmolof actagardine and 4 mmolof cyclopentylpiperazine dihydrochloride in 10ml of DMF,10mmol of TEAwas added while cooling at 0°C; afterward the usual general procedure was followed.
Dicarboxamides (Compounds ll and 12) To a stirred solution of 1 g (about 0.5 mmol) of actagardine, 2.1 mmol of ethylamine or glycine ethyl SEPT. 1990 ester, as the hydrochlorides, and 0.5 ml (about 3.6mmol) of TEA in 100ml of DMF, a solution of 0.27ml (1.23mmol) ofDPPA in 2.5ml ofDMF was added dropwise at 0^5°C in 15 minutes. After 6 hours at 5°C, the reaction mixture was kept at room temperature overnight. On adding Et2O (about 500ml), a solid separated which was collected and redissolved in 100 ml of cold 0.01 N HC1. The solution was extracted with 100ml of BuOH.The organic layer was washed with 100ml of 0.1 Mphosphate buffer pH 7.38, then with H2O; afterward the solvent was evaporated and the solid residue was redissolved in 30 ml of 95 %EtOH. The resulting solution was filtered. On adding Et2O, a solid separated which was collected, washed with Et2O, and then dried under vacuumat room temperature overnight, yielding the appropriate title compound, as the free base.
Compound 13
To a stirred solution of 0.378 g (1 mmol) of hexadecanoic acid/?-nitrophenyl ester in 25 ml of DMSO, 0.400 g (about 0.2 mmol) of actagardine and 0.070 ml (0.5 mmol) of TEA were added at room temperature. After 6 hours, the reaction mixture was kept at room temperature in the dark for 1 week; afterward it was adjusted at pH 3.5 with 3 N HC1, and then it was poured into 200ml of ice cold H2O. Extraction with BuOH and evaporation of the organic solvent yielded a crude oily residue which was triturated with Et2O. The separated solid was collected, washed with Et2O, and then dried under vacuum at room temperature overnight to give 0.27 g of the title compound.
Determination of Antibacterial Activity Susceptibility Testing MICwas determined by 2-fold serial dilution method in microtiter (Staphylococci) or in tube (Streptococci). Brain heart infusion broth (Difco) was used; it was supplemented with 2% bovine serum whenStreptococci were tested. The inocula were approximately 103 or 106 cfu/ml to determine the influence of inoculum size on antibacterial activity. The influence of serum was determined on Staphylococcus aureus Tour by adding 30%bovine serum to the medium. MIC was defined as the lowest concentration that prevents visible growth after incubation at 37°C for 18~24 hours.
Bactericidal Activitv The bactericidal activity of compound 4 was compared to that of actagardine. The antibiotics were added at concentrations equal or multiple of the MICto growing cells of S. pyogenes C 203 SKF 13400 in Todd-Hewitt broth (Difco). The cultures were incubated at 37°C in a water bath with shaking and viable cells were counted at intervals. ExperimentalInfection Experimental septicemia was induced in groups of 5 mice by ip injection of a suspension of the test pathogens. Inocula had been adjusted so that the untreated animals died within 48 hours. Mice were treated by sc or po route once a day for 3 days starting about 30 minutes after infection. Onthe 10th day the ED50 infected animals, expressed in mg/kg was calculated on the bases of the percentage of surviving mice at each dose, by the Spearmann and Karber method.8)
